CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dancann Pharma A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dancann Pharma A/S
Rugvaenget 5
ANSAGER, 6823  Denmark Ticker: DANCANDANCAN

Business Summary
Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202412/31/2023Yes----

Subsidiaries
Business Name Address City State/Province Country
Canngros ApS Jens Grons Vej 21 Vejle Denmark

Business Names
Business Name
Canngros ApS
DAN
DANCAN
DCPXF

General Information
Number of Employees: 12 (As of 12/31/2023)
Outstanding Shares: 1,206,101,235 (As of 6/30/2024)
Stock Exchange: AKT


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024